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Hyperlipidemia aggravates renal disease in B6.ROP Os/+mice.
Introduction. Reduction of renal mass is frequently associ-
ated with progressive loss of kidney function. We examined the
effects of hyperlipidemia on renal pathology and mediators of
tissue damage in B6.ROP Os/+ mice, a model of reduced renal
mass.
Methods. C57BL/6 control mice and B6.ROP Os/+ mice were
fed normal rodent chow or a high fat, high cholesterol (HFHC)
diet for 12 weeks. Kidney function and renal pathology were
assessed.
Results. Hyperlipidemia led to a decline in kidney function
in C57BL/6 mice. Renal pathology was characterized by an
increase in glomerular matrix and cellularity, glomerular and
tubulointerstitial macrophage influx, and increased tubular ep-
ithelial cell turnover. Chow-fed B6.ROP Os/+ animals demon-
strated glomerular hypertrophy with an increase in mesangial
matrix and cellularity that was characterized by macrophage in-
flux and increased proliferation. The tubulointerstitium showed
increased macrophages as well as tubular atrophy and dilation.
Renal pathology was accompanied by an increase in blood urea
nitrogen (BUN) and proteinuria. Hyperlipidemia in B6.ROP
Os/+ mice resulted in increased plasma BUN compared to
chow-fed B6.ROP Os/+ animals and aggravated renal pathol-
ogy by further increasing glomerular matrix and glomerular
hypercellularity. Glomerular hypercellularity was associated
with increased expression of platelet-derived growth factor-B
(PDGF B) and its receptor b . Glomerular transforming growth
factor-b (TGF-b) mRNA expression was increased in B6.ROP
Os/+ mice, hyperlipidemic C57BL/6 mice and hyperlipidemic
B6.ROP Os/+ animals compared to controls and correlated
with the amount of mesangial matrix.
Conclusion. This study demonstrates that hyperlipidemia
worsens renal pathology in B6.ROP Os/+ mice with a decline in
renal function mediated at least in part through increased renal
expression of the cytokines PDGF B and TGF-b .
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The reduction of glomerular filtration rate (GFR)
below 50% of normal has been associated with a pro-
gressive loss of kidney function, even after the original
disease becomes inactive [1, 2]. There have been reports
that up to 30% of patients with greater then 50% reduc-
tion of total renal mass develop systemic hypertension
and 70% develop significant proteinuria, in some cases
leading to end-stage renal disease (ESRD) [3, 4]. How-
ever, since most patients after unilateral nephrectomy are
able to maintain normal kidney function it is clear that
additional nonimmune mechanisms are important in the
pathogenesis of chronic renal injury. Here, we assess the
effects of two physiologic processes, reduced renal mass
and hyperlipidemia, that have both been strongly impli-
cated as key mediators of progressive renal injury. To
study the role of reduced renal mass we utilized the ROP
Os/+ mouse strain, which carries a radiation-induced
mutation of the Os gene located on chromosome 8 [5,
6]. A homozygous mutation in this locus is associated
with early postimplantation lethality, whereas heterozy-
gous mice develop oligosyndactyly and 38% reduction
in renal mass [7]. Mice develop an approximately 50%
decrease in nephron number with a compensatory in-
crease in glomerular volume and tubular hypertrophy
[7]. This increase in glomerular volume is due to a sig-
nificant expansion of the mesangial matrix area with ac-
cumulation of collagen IV and tenascin as well as an in-
crease in glomerular cell number and concomitantly in-
creased thymidine labeling index [8]. The Os mutation
was originally described in ROP mice, which were shown
to be a sclerosis prone strain [9, 10]. The B6.ROP Os/+
strain has all the biologic features of the Os mutation
but is on a C57BL/6 genetic background, and not on a
ROP background, despite the similarities in nomencla-
ture. This strain is neutral with respect to susceptibility to
glomerulosclerosis, and is more resistant to sclerosis than
the ROP strain originally used for studies of the renal
effects of the Os mutation.
Abnormal lipid metabolism frequently accompanies
renal disease and is thought to be involved in the
pathogenesis of renal injury. Clinical observations have
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suggested a role of hyperlipidemia as a modulator of pro-
gression of primary kidney diseases. Nondiabetic patients
with proteinuria and elevation in serum cholesterol and
triglycerides had a nearly twofold increase in the rate of
loss of renal function compared to normolipidemic pa-
tients [11, 12] and treatment with lipid-lowering agents
has been demonstrated to reduce levels of circulating
cholesterol and to stabilize or improve renal function [13–
15]. However, the relationship between hyperlipidemia
and renal injury remains incompletely understood. The
aim of this study was to gain further insight into the ef-
fects of hyperlipidemia on renal pathology and kidney
function in a model of reduced renal mass, the B6.ROP
Os/+ mouse.
METHODS
Animal study and experimental design
Female C57BL/6 and male B6.ROP Os/+ mice were
obtained from the Jackson Laboratory (Bar Harbor, ME,
USA). C57BL/6 females were bred with the B6.ROP
Os/+ males to generate mice heterozygous for the Os
gene. Female C57BL/6 control mice and B6.ROP Os/+
were fed either a rodent chow diet (N = 5 and N =
6, respectively), or a high fat, high cholesterol (HFHC)
diet (N = 5, and N = 8, respectively) as described be-
low. Mice were maintained in a temperature-controlled
room (22◦C) with a 12-hour light/dark cycle and given
free access to food and water. Food was removed from
the mice 4 hours prior to the collection of blood from
the retroorbital sinus into tubes containing anticoagulant
[1 mmol/L ethylenediaminetetraacetic acid (EDTA)].
Plasma was stored at −70◦C until analysis. Mice were
killed by cervical dislocation and tissues were snap frozen
in liquid nitrogen and stored at −70◦C.
Diets and feeding
Two diets were used in this study. The first was pel-
leted rodent chow (Wayne Rodent BLOX 8604), which
served as a reference diet and contained by weight ap-
proximately 4% fat, 24% protein, and 4.5% crude fiber
(manufacturer’s estimates). All mice were fed the rodent
chow diet until 20 weeks of age when the test diet was
initiated in the experimental group. The test diet was a
HFHC diet that contained 15% fat, 1.25% cholesterol,
and 0.5% sodium cholate (TD 92001) (Harlan Teklad,
Madison WI, USA). Mice were fed the HFHC diet for 12
weeks.
Analytical procedures
Total plasma cholesterol was assessed colorimetri-
cally using a kit from Diagnostic Chemicals Limited
(Diagnostic Chemicals Limited, Oxford, CT, USA)
with cholesterol standards (Preciset #12552) (Boehringer
Mannheim, Indianapolis, IN, USA). Plasma triglyceride
levels were determined after the removal of free glyc-
erol using a colorimetric kit (Diagnostic kit # 450032)
(Boehringer Mannheim). Plasma blood urea nitrogen
(BUN) levels were measured using a colorimetric assay
from Sigma (Diagnostic kit #535-A) (Sigma Chemical
Co., St. Louis, MO, USA). Urinary protein excretion was
assessed with urine test strips (Uristix) (Bayer, Elkhart,
IN, USA) in a semiquantitative fashion. Glucose and in-
sulin levels were measured at the Northwest Lipid Re-
search Laboratories, University of Washington.
Tissue preparation and histologic staining
At the end of the study mice were sacrificed by cer-
vical dislocation and whole animals were perfused with
10 mL of antioxidant buffer [100 lmol/L diethylenetri-
ame pentaacetic acid (DTPA), 100 lmol/L, butylated hy-
droxytoluene (BHT), and 0.1% ethanol in phosphate-
buffered saline (PBS), pH 7.4] via the left ventricle. Kid-
neys were removed and fixed in 10% neutral buffered for-
malin or methyl Carnoy’s solution (60% methanol, 30%
chloroform, and 10% acetic acid) for histologic examina-
tion. Small portions of kidney tissue were fixed in half
strength Karnovsky’s solution for electron microscopy
(1% paraformaldehyde and 1.25% glutaraldehyde in 0.1
mol/L Na cacodylate buffer, pH 7.0). Tissues were pro-
cessed and embedded in paraffin using standard protocols
and cut into 2 lm sections for periodic acid-methenamine
silver stain (PAM) or in 4 lm sections for hematoxylin
and eosin staining, immunohistochemistry or terminal
deoxy transferase uridine triphosphate nick end labeling
(TUNEL) staining.
Immunohistochemistry and TUNEL staining
Tissue sections were deparaffinized in xylene and re-
hydrated in graded ethanol to use for immunohisto-
chemistry. Where necessary, antigen retrieval was per-
formed by heating tissue sections in Antigen Unmasking
Solution (Vector Laboratories, Burlingame, CA, USA).
Endogenous peroxidases were blocked by immersing the
tissue in 3% hydrogen peroxide and endogenous biotin
was blocked using the Avidin/Biotin blocking kit (Vec-
tor Laboratories). Primary antibodies were diluted in 1%
bovine serum albumin (BSA) (Sigma Chemical Co.) in
PBS and sections were incubated for 1 hour at room
temperature. After repeated washing steps slides were
incubated with the appropriate biotinylated secondary
antibody for 30 minutes. Signal amplification was per-
formed with the Vector ABC-Elite Reagent and 3, 3′-
diaminobenzidine (DAB) (Sigma Chemical Co.) with
nickel enhancement was used a chromogen resulting
in a black color product. Tissue sections were counter-
stained with periodic acid-Schiff (PAS)/methyl green, de-
hydrated and coverslipped.
Macrophages were detected with a rat anti-mouse
Mac-2 antibody from Cederlane (Cederlane, Ontario,
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Canada) as described previously [16]. Mesangial cell
activation and smooth muscle–like transformation was
assessed with a mouse monoclonal IgG2a antibody
against a-smooth muscle actin (a-SMA) (clone 1A4)
(Dako, Carpenteria, CA, USA), previously described
in [17]. An antibody against human proliferating cell
nuclear antigen (PCNA) (Oncogene Research Prod-
ucts, Cambridge, MA, USA) was used to show cellular
proliferation (previously described in [18]). Glomeru-
lar apolipoprotein B deposition was stained with a rab-
bit polyclonal antibody generously provided by J. Born.
Appropriate secondary antibodies were all from Vector
Laboratories except for antimouse IgG2a, which was pur-
chased from Pharmingen (San Diego, CA, USA).
TUNEL staining was performed using the TdT-FragEL
DNA fragmentation detection kit (Oncogene Research
Products) according to the manufacturer’s instructions
and previously described in detail [19]. In brief, tissue sec-
tions were deparaffinized, rehydrated, and permeabilized
in 20 lg/mL proteinase K in 10 mmol/L Tris. Endogenous
peroxidases were blocked in 3% hydrogen peroxide in
methanol. After that slides were labeled with TdT la-
beling reaction mix and incubated for 1.5 hours at 37◦C.
The resulting signal was amplified with the ABC-Elite
reagent (Vector Laboratories) and visualized with DAB
and nickel enhancement. Finally, the slides were coun-
terstained with PAS and methyl green, dehydrated, and
coverslipped.
In situ hybridization
In situ hybridization was performed on formalin fixed
tissue after washing in 0.5× standard saline citrate (SSC)
(1× SSC = 150 mmol/L NaCl and 15 mmol/L Na cit-
rate, pH 7.0) and digestion with 25 lg/mL proteinase K
(Sigma Chemical Co.) for 30 minutes at 37◦C. Several
washes with 0.5× SSC are followed by a 2-hour incu-
bation with prehybridization buffer [0.3 mol/L NaCl, 20
mmol/L Tris, pH 8.0, 5 mmol/L EDTA, 1× Denhardt’s so-
lution, 10% dextran sulfate, and 10 mmol/L dithiothreitol
(DTT)]. The hybridization process was started by adding
500,000 cpm 35S-labeled probe in prehybridization buffer
to the slides and allowed to proceed overnight at 50◦C.
After hybridization the slides were washed in 2× SSC
and treated with RNase A (20 lg/mL). Rinsing in 2×
SSC was followed by three high-stringency washing steps
in 0.1× SSC + 0.1% Tween 20 (Sigma Chemical Co.) at
50◦C and several 2× SSC washes. The tissue was then
dehydrated in graded ethanol, air-dried, and dipped in
NTB2 nuclear emulsion (Kodak, Rochester, NY, USA).
Slides were exposed in the dark for 2 to 5 weeks at 4◦C.
After developing the sections were counterstained with
hematoxylin and eosin.
Probes used for in situ hybridization were transform-
ing growth factor-b (TGF-b1), platelet-derived growth
factor-B (PDGF-B), PDGF receptor b , and monocyte
chemoattractant protein-1 (MCP-1) and have been de-
scribed in detail [20].
Electron microscopy
Randomly selected cases of each experimental group
were utilized for electron microscopy and processed as
described previously in detail [21]. Grids were scanned
using a Philips 410 electron microscope (Philips, Eind-
hoven, The Netherlands).
Quantitative analysis and statistics
Morphometric analysis was performed by using the Im-
age Pro Plus software (Media Cybernetics, Silver Spring,
MD, USA). Fifteen random glomerular cross-sections per
experimental animal were photographed by a blinded ex-
aminer using a digital camera (Olympus DP11) (Olym-
pus America, Melville, NY, USA). Hematoxylin and
eosin–stained sections were used for the assessment of
glomerular cellularity while the amount of extracellu-
lar matrix was evaluated using PAM silver stains and
immunohistochemistry for collagen IV. The number of
macrophages and proliferating cells was counted in at
least 20 random glomerular cross-sections or high power
fields. Glomerular a-SMA expression in mesangial areas
was assessed semiquantitatively on a scale from 0 (neg-
ative) to 4 (strong global expression) as previously de-
scribed [22]. Intraglomerular expression of mRNA for
different probes was scored using a similar semiquantita-
tive system in which 0 corresponded to no expression, 1
to only a few positive cells, 2 to several positive cells, and
3 to many positive cells in a diffuse distribution.
Values are expressed as mean ± SEM. Statistical differ-
ences were calculated using the SPSS software (SPSS Inc.,
Chicago, IL, USA). Means between groups were com-
pared using analysis of variance (ANOVA) with Tukey’s
post hoc test. A P value of P < 0.05 was considered sta-
tistically significant. Association between PDGF-B and
glomerular cellularity as well as TGF-b and glomeru-
lar matrix and collagen IV expression was calculated
using the nonparametric Spearman rank correlation
coefficient.
RESULTS
Hyperlipidemia reduced kidney function and induced
renal pathology in C57BL/6 mice
Feeding of a HFHC diet to C57BL/6 mice led to
a significant increase in plasma cholesterol from 63 ±
4 mg/dL in control animals to 249 ± 27 mg/dL in the
HFHC diet (P < 0.01) (Table 1) while plasma triglyc-
erides levels decreased from 36 ± 5 mg/dL for controls to
9 ± 1 mg/dL in animals on the HFHC diet. These changes
in lipid metabolism were accompanied by a significant in-
crease in plasma BUN in the hyperlipidemic group (26 ±
2 mg/dL in controls vs. 41 ± 4 mg/dL in hyperlipidemic
animals) (P < 0.05) (Table 1) and a significant increase
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Table 1. Laboratory data
C57BL/6, C57BL/6, B6.ROP Os/+, B6.ROP Os/+,
chow high fat diet chow high fat diet
Cholesterol mg/dL 65 ± 4 249 ± 27b 71 ± 3 361 ± 41b,f
Triglycerides mg/dL 35 ± 5 9 ± 1b 34 ± 4 18 ± 3b,e
BUN mg/dL 26 ± 2 41 ± 4a 45 ± 4b 62 ± 2c,d,g
Proteinuriah 0.4 ± 0.2 1.4 ± 0.2a 1.5 ± 0.2b 1.9 ± 0.1c
Glucose mg/dL 143 ± 6d 127 ± 23d 200 ± 10a 108 ± 5d
Insulin ng/mL 0.4 0.2 ± 0.1 0.4 ± 0.1 0.2 ± 0.0
BUN is blood urea nitrogen.
Lipid metabolism and kidney function in chow fed C57BL/6 wild-type and B6.ROP Os/+ mice and C57BL/6 and B6.ROP Os/+ animals on a high fat diet. Data
expressed as mean ± SEM. Statistical significances compared to wild-type controls (aP < 0.05, bP < 0.01, cP < 0.001) or compared to chow-fed B6.ROP Os/+ animals
(dP < 0.05, eP < 0.01, fP < 0.001).
gMarks statistically significant differences at a level of P < 0.01 between hyperlipidemic C57BL/6 mice and hyperlipidemic B6.ROP Os/+ animals.
hProteinuria assessed by dipstick: 1 = 30 mg/dL, 2 = 100 mg/dL.
Table 2. Morphometric data
C57BL/6, C57BL/6+, B6.ROP Os/+, B6.ROP Os/+,
chow high fat diet chow high fat diet
Glomerular size lm2 3679 ± 134 4394 ± 140 6045 ± 383c 5414 ± 159c,g
Extracellular matrix/gcs lm2 179 ± 15 325 ± 30b 355 ± 29b 396 ± 24c
Extracellular matrix/area % glomerular area 4.5 ± 0.4 7.7 ± 0.3c 5.8 ± 0.3a 7.1 ± 0.3c,d
Collagen IV/gcs lm2 237 ± 24 399 ± 29b 563 ± 28c 673 ± 25c,e,h
Collagen IV/area % glomerular area 6.1 ± 0.3 8.1 ± 0.4 8.7 ± 0.2c 12.2 ± 0.4c,d
Cellularity cells/gcs 43 ± 2 58 ± 1b 64 ± 4c 66 ± 2c
Cellularity/area % glomerular area 12 ± 0.2 14 ± 0.2b 11 ± 0.5a 12 ± 0.2e,g
Proliferation PCNA-positive cell/gcs 0 ± 0 0.2 ± 0.08 0.3 ± 0.11a 0.1 ± 0.04
Proliferation PCNA-positive cell/hpf 1.2 ± 0.3 7.4 ± 0.8b 1.8 ± 0.2 9.8 ± 1.4c,f
Glomerular apoptosis 0.000 ± 0.000 0.020 ± 0.010 0.013 ± 0.006 0.006 ± 0.004
TUNEL-positive cells/gcs NS NS NS
Tubulointerstitial apoptosis 0.0 ± 0.0 0.8 ± 0.4 0.5 ± 0.2 0.6 ± 0.2
TUNEL-positive cells/20 hpf NS NS NS
Macrophage infiltration Mac-2–positive cells/gcs 1.2 ± 0.2 0.9 ± 0.2 3.6 ± 0.7b 2.0 ± 0.1d
Macrophage infiltration Mac-2–positive cells/hpf 0.2 ± 0.0 3.6 ± 0.4b 2.5 ± 0.6a 3.7 ± 0.5c
a-smooth muscle actin expression 0.0 ± 0.01 0.2 ± 0.04a 0.6 ± 0.03c 0.3 ± 0.02c,f,h
Abbreviations are: gcs, glomerlar cross-section; hpf, high power field; PCNA, proliferating cell nuclear antigen; TUNEL, terminal deoxy transferase uridine
triphosphate nick end labeling.
Morphometric analysis of kidney sections from chow-fed wild-type and B6.ROP Os/+ mice and C57BL/6 and B6.ROP Os/+ animals on a high fat diet. Data
expressed as mean ± SEM. Statistical significances compared to wild-type controls (aP < 0.05, bP < 0.01, cP < 0.001) or compared to chow fed B6.ROP Os/+ animals
(dP < 0.05, eP < 0.01, fP < 0.001). Statistically significant differences between both hyperlipidemic groups are expressed as gP < 0.05 and hP < 0.01.
in urinary protein excretion (0.4 ± 0.2 units in C57BL/6
mice vs. 1.4 ± 0.2 units in mice fed the HFHC diet) (P <
0.05) (Table 1).
This decline in kidney function by hyperlipidemia cor-
related with the induction of renal pathology in C57BL/6
mice. Hyperlipidemic mice showed modest amounts of
glomerular staining for apolipoprotein B, which was ab-
sent in normolipidemic mice (Fig. 5). Glomerular lesions
were represented by an increase in mesangial a-SMA ex-
pression (score of 0.0 ± 0.0 in wild-type mice vs. 0.2 ±
0.0 in animals fed the HFHC diet) (P < 0.05) (Table 2)
(Fig. 3). This indication of mesangial cell activation cor-
responded to a twofold increase in mesangial matrix (P <
0.01) and glomerular collagen IV (P < 0.001) in hyperlipi-
demic mice compared to normal control mice (Table 2)
(Fig. 1). Glomeruli of hyperlipidemic C57BL/6 mice also
demonstrated modest hypercellularity with an increase
in cell number from 43 ± 2 cells/glomerular cross-section
in control mice to 58 ± 1 cells/glomerular cross-section in
animals fed the HFHC diet (P < 0.01) (Table 2) (Fig. 1).
Proliferation and apoptotic cell death, assessed by PCNA
and TUNEL staining, were not different between mice on
normal chow and animals fed a HFHC diet. Glomeru-
lar macrophage content was only slightly elevated in
hyperlipidemic mice compared to controls but glomeru-
lar macrophages had frequently foam cell appearance
(Table 2) (Fig. 2).
In addition to the glomerular changes induced by
hyperlipidemia, mice on the HFHC diet also demon-
strated tubulointerstitial pathology. Hyperlipidemic mice
showed occasional staining for apolipoprotein B in in-
filtrating cells in the tubulointerstitium, morphologically
most likely representing macrophages (Fig. 5). They had
a large influx of macrophages into the tubulointerstitium
(3.6 ± 0.4 mac-2–positive cells/high power field vs. 0.2
± 0.0 cells/high power field in control mice) (P < 0.01)
(Table 2) (Fig. 4). Hyperlipidemic mice showed signs of
fatty degeneration of the tubular epithelium and cellular
proliferation was significantly increased in the tubular
epithelium (1.2 ± 0.3 PCNA positive cells/high power
field in control mice vs. 7.4 ± 0.8 cells/high power field in
mice fed the HFHC diet) (P < 0.01) (Table 2).
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Fig. 1. Glomerular architecture in control and hyperlipidemic mice.
(A) Normal glomerular architecture in a chow fed C57BL/6 wild-
type mouse. (B) C57BL/6 animal, high fat, high cholesterol diet. The
glomerulus shows a segmental increase in extracellular matrix. (C)
Glomerulus from a chow-fed B6.ROP Os/+ mouse with segment ex-
pansion of the mesangial matrix and adhesion of the glomerular tuft to
Bowman’s capsule (arrow). (D) B6.ROP Os/+ animal fed the high fat,
high cholesterol diet. The glomerulus demonstrates an area of mesan-
giolysis (∗) and a prominent foam cell (arrow).
B6.ROP Os/+ mice showed glomerular hypertrophy and
mesangial accumulation of extracellular matrix
B6.ROP Os/+ mice demonstrated a significant decline
in renal function compared to C57BL/6 control mice.
Plasma BUN levels were elevated to 45 ± 4 mg/dL com-
pared to 26 ± 2 mg/dL in controls (P < 0.01) (Table 1)
and proteinuria increased from 0.4 ± 0.2 × in C57BL/6
animals to 1.5 ± 02 × in mice with the Os gene (P < 0.01)
(Table 1). Plasma cholesterol and triglycerides levels re-
mained unchanged.
Renal pathology was remarkable for glomerular hyper-
trophy, demonstrated by an increase in glomerular size
(3679 ± 134 lm2 in controls vs. 6045 ± 383 lm2 in B6.ROP
Os/+ mice) (P < 0.001) (Table 2) (Fig. 1). This increase
in glomerular area resulted from an increase in cellular-
ity (43 ± 2 cells/glomerular cross-section in control mice
vs. 64 ± 4 cells/glomerular cross-section in B6.ROP Os/+
mice) (P < 0.001) and accumulation of extracellular ma-
trix. The hypercellularity was the result of an increase in
cell proliferation as assessed by PCNA stain (P < 0.05)
(Table 2), as well as an influx of macrophages (1.2 ± 0.2
macrophages/glomerular cross-section in control mice vs.
3.6 ± 0.7 cells/glomerular cross-section in B6.ROP Os/+
mice) (P < 0.01). The silver-stained area of the glomeru-
lus, representing extracellular matrix, increased from 179
± 15 lm2 in wild-type animals to 355 ± 29 lm2 in B6.ROP
Os/+ mice (P < 0.01) (Table 2) (Fig. 1). A similar increase
was noted for collagen IV, an important component of ex-
Fig. 2. Glomerular macrophage influx in control and hyperlipidemic
mice. (A) Chow-fed C57BL/6 wild-type mice show only occasional
glomerular macrophages. (B) Feeding of a high fat, high cholesterol diet
to C57BL/6 mice does not increase glomerular macrophage influx but
leads signs of lipid accumulation (foam cells). (C) Chow fed B6.ROP
Os/+ animals show increased levels of glomerular macrophages. (D)
B6.ROP Os/+, fed a high fat, high cholesterol diet show high levels of
glomerular macrophages and foam cells.
tracellular matrix (237 ± 24 lm2 in C57BL/6 controls vs.
563 ± 28 lm2) (P < 0.001). The a-SMA score, a mea-
sure for mesangial cell activation, was also elevated in
B6.ROP Os/+ mice (P < 0.001) (Table 2) (Fig. 3). No sig-
nificant staining for apolipoprotein B could be detected in
the glomeruli or the tubulointerstitium of B6.ROP Os/+
mice.
The tubular parenchyma showed a modest degree
of tubular dilation and atrophy. The tubulointerstitium
demonstrated high number of macrophages (P < 0.05)
(Table 2) (Fig. 2). Cellular turnover of tubular epithe-
lial cells was not changed compared to control mice. No
significant fibrosis was noted.
Hyperlipidemia led to a further decline in renal function
in B6.ROP Os/+ mice
Feeding of the HFHC diet led to a significant in-
crease in plasma cholesterol in B6.ROP Os/+ mice (361 ±
41 mg/dL with HFHC diet vs. 71 ± 3 mg/dL on regular
chow) (P < 0.001) (Table 1). Triglyceride levels were de-
creased by the HFHC diet (36 ± 5 mg/dL on normal diet
vs. 18 ± 3 mg/dL on the HFHC diet) (P < 0.01). Hyperlipi-
demic B6.ROP Os/+ mice had a further decline in renal
function compared to normolipidemic B6.ROP Os/+ an-
imals as expressed by an increase of plasma BUN from 45
± 4 mg/dL on the chow diet to 62 ± 2 mg/dL on the HFHC
diet (P < 0.05) but proteinuria remained unchanged to
the elevated levels of normolipidemic B6.ROP Os/+.
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Fig. 3. Glomerular a-smooth muscle actin staining (a-SMA) in control
and hyperlipidemic mice. Chow-fed C57BL/6 wild type mice (A) and
C57BL/6 mice fed a high fat diet (B) did not show glomerular a-SMA
staining and demonstrated positivity only in the arterioles. (C) Chow-
fed B6.ROP Os/+ animals show a strong increase in mesangial positivity
for a-SMA indicating activation of mesangial cells and changes toward
a smooth muscle-like phenotype. (D) B6.ROP Os/+ mice fed a high
fat, high cholesterol diet demonstrate strong positivity for a-SMA but
decreased expression in areas of fat accumulation and mesangiolysis.
Hyperlipidemia aggravated renal pathology in B6.ROP
Os/+ mice
Hyperlipidemic B6.ROP Os/+ mice had significant
glomerular hypertrophy compared to wild type mice
(5414 ± 159 lm2 vs. 3679 ± 134 lm2 in C57BL/6 ani-
mals) (P < 0.001) but glomerular architecture was more
altered then in normolipidemic B6.ROP Os/+ animals.
Glomeruli frequently displayed signs of mesangiolysis;
a-SMA expression, although still elevated compared to
C57BL/6 control mice, was decreased in these areas
(Table 2) (Fig. 3). Glomeruli commonly showed mesan-
gial lipid deposits and diffuse or focal staining for
apolipoprotein B (Fig. 5), mostly in the area of the vascu-
lar pole. Glomerular extracellular matrix increased from
occupying 5.8 ± 0.3% to 7.1 ± 0.3% of the glomerular
area in hyperlipidemic mice (P < 0.05) and glomeru-
lar collagen IV expression increased from 8.7 ± 0.2%
to 12.2 ± 0.4% in animals fed the HFHC diet com-
pared to normolipidemic B6.ROP Os/+ mice (P < 0.05).
In addition, hypercellularity also increased in hyper-
lipidemic B6.ROP Os/+ mice compared to normolipi-
demic controls from a cellular area of 10.5 ± 0.5% of
the glomerulus to 12.4 ± 0.2%, respectively (P < 0.01)
(Table 1). However, glomerular proliferation rate was un-
changed and glomerular macrophage content was even
slightly lower then in normolipidemic mice (2.0 ± 0.1
mac-2–positive cells/glomerular cross-section vs. 3.6 ± 0.7
mac-2–positive cells/glomerular cross-section in chow-
fed B6.ROP Os/+ mice) (P < 0.05) (Fig. 2) though
macrophages were mostly foam cell–like in appearance
and sometimes demonstrated staining for apolipoprotein
B (Fig. 5).
Tubulointerstitial changes in hyperlipidemic B6.ROP
Os/+ animals included fatty tubular degeneration in ad-
dition to the tubular atrophy and dilation seen in B6.ROP
Os/+ mice on a regular diet. Tubular epithelial cells had
a significantly increased cell turnover with PCNA stain-
ing cells being increased from 1.8 ± 0.2/high power field
in normolipidemic mice to 9.8 ± 1.4 positive cells/high
power field in hyperlipidemic B6.ROP Os/+ animals (P <
0.001) (Fig. 4) and tubular TUNEL staining was also ele-
vated although they did not reach the level of statistical
significance (0.1 ± 0.0 TUNEL-positive cells/high power
field in B6.ROP Os/+ mice vs. 0.6 ± 0.0 TUNEL-positive
cells/high power field in B6.ROP Os/+mice on the HFHC
diet) (P = 0.099) (Fig. 4). Tubulointerstitial macrophage
influx was elevated compared to C57BL/6 control mice
and macrophages had mostly a foam cell–like phenotype
(0.2 ± 0.0 in control animals vs. 3.7 ± 0.5 cells/high power
field in hyperlipidemic B6.ROP Os/+ mice) (P < 0.001).
The tubulointerstitium also showed infiltrating cells that
stained positive for apolipoprotein B (Fig. 5).
Influences of the ROP Os/+ mutation on kidney function
and renal pathology in hyperlipidemic mice
Reduction of renal mass by the ROP mutation led to an
increase in plasma BUN in B6.ROP mice on the HFHC
diet compared to wild-type mice on HFHC diet while
proteinuria was not further increased (Table 1). Glomeru-
lar injury in hyperlipidemic B6.ROP mice seemed to be
aggravated compared to wild-type mice on the HFHC
diet as expressed by an increase in glomerular size and
glomerular collagen IV accumulation (Table 2) (Fig. 1).
In addition, glomerular a-SMA expression was increased
in hyperlipidemic B6.ROP mice compared to hyperlipi-
demic wild-types (Fig. 3). The reduction in glomerular
mass induced by the ROP Os/+ mutation seemed to have
no influence on glomerular macrophages, proliferating
cells, or apoptotic cells which were not different between
both hyperlipidemic groups. Markers of tubulointerstitial
changes like macrophage influx and tubuloepithelial cell
turnover measured in proliferating and apoptotic cells
were also not significantly different between these two
groups.
Electron microscopy
Electron microscopy in a few selected cases showed
an expansion of the mesangium in chow-fed B6.ROP
Os/+ mice with an increase in actin filaments. Mesangial
areas displayed frequent infiltration with macrophages.
Hyperlipidemia led to the deposition of fat in the mesan-
gial matrix and in the subendothelial areas of capillary
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Fig. 4. Tubular changes in control and hyperlipidemic mice. (A) Low
power view of the tubulointerstitium of a B6.ROP Os/+ mouse fed a
high fat, high cholesterol diet stained for macrophages (Mac-2) and
counterstained with periodic acid-Schiff (PAS)/methyl green. The pho-
tographs show prominent macrophage invasion in areas of tubular
damage (arrow). (B, C, and D) Representative tubulointerstitial areas
stained with the proliferation marker proliferating cell nuclear antigen
(PCNA). (B) Only occasional cellular positivity in a wild-type mouse.
(C) A B6.ROP Os/+ animal with typical tubular dilation (∗) and associ-
ated proliferation of tubular epithelial cells. (D) B6.ROP Os/+ animal
fed a high fat, high cholesterol diet with high levels of tubular epithelial
cell proliferation in areas of tubular damage. (E, F, and G) Terminal de-
oxy transferase uridine triphosphate nick end labeling (TUNEL) stain-
ing for apoptotic cell death. Wild-type animals (E) show rare apoptotic
cells while chow-fed B6.ROP Os/+ animals (F) and B6.ROP Os/+ mice
fed a high fat, high cholesterol diet (G) showed increased apoptotic rates
in areas of tubular damage.
walls as well as to the infiltration of the mesangium with
macrophages with a foam cell appearance (Fig. 6).
Renal pathology was associated with changes in the ex-
pression levels of glomerular cytokines and chemokines
In situ hybridization was performed to assess whether
changes in renal pathology were mediated by glomeru-
lar expression of different cytokines and chemokines.
Glomerular expression of TGF-b mRNA was increased
in hyperlipidemic C57BL/6 mice, B6.ROP Os/+ mice,
and hyperlipidemic B6.ROP Os/+ animals (relative
scores of 0.2 ± 0.1 in normal controls to 1.6 ± 0.2, 1.3
± 0.2, and 1.4 ± 0.1, respectively) (P < 0.001). The in-
traglomerular expression of TGF-b mRNA correlated
with the amount of extracellular matrix assessed by black
Fig. 5. Apolipoprotein B staining in control and hyperlipidemic mice.
(A) Representative glomerulus from a chow-fed C57BL/6 mouse,
no significant staining for apolipoprotein B. (B) Chow-fed B6.ROP
Os/+, no significant staining for apolipoprotein B. (C) Glomeruli for
C57BL/6 mice fed a high fat, high cholesterol diet show diffuse stain-
ing for apolipoprotein B. (D and E) Diffuse glomerular staining for
apolipoprotein B with focal concentration in the area of the vascu-
lar pole in B6.ROP Os/+ animal fed a high fat, high cholesterol diet.
(F) Apolipoprotein B staining in infiltrating tubulointerstitial cells and
glomerular foam cell (insert) of tissue from a B6.ROP Os/+ animal fed
a high fat, high cholesterol diet.
staining material in PAM stain (r = 0.53, P < 0.01) and
with glomerular collagen IV content (r = 0.59, P < 0.01).
It also showed a significant association with intraglomeru-
lar macrophage content (r = 0.55, P < 0.01), which has
previously shown to be a contributor to total glomerular
TGF-b expression [23, 24].
Similarly, hyperlipidemic control mice and ROP Os/+
mice showed a strong increase in glomerular PDGF-B
mRNA expression and its receptor PDGF receptor b with
a further increase in hyperlipidemic ROP Os/+ animals
(Table 3). Both, PDGF-B and its receptor, correlated with
glomerular cellularity (r = 0.63, P < 0.01 and r = 0.5,
P < 0.05, respectively).
Renal expression of the chemoattractant MCP-1 was
generally low with no positive cells in control mice and
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Fig. 6. Hyperlipidemic mice show ultrastructural alterations. (A)
B6.ROP Os/+ mouse fed a high fat, high cholesterol diet. The mesangial
area is expanded with an increase in dense bodies representing actin fil-
aments and macrophage invasion. (B) B6.ROP Os/+ animal fed a high
fat, high cholesterol diet. Electron microscopy reveals fat droplet in the
mesangial area (arrow). (C) Expansion of the subendothelial area (∗)
in a B6.ROP Os/+ mouse on a high fat, high cholesterol diet.
Table 3. Glomerular cytokine mRNA expression
C57BL/6, C57BL/6+, B6.ROP Os/+, B6.ROP Os/+,
chow high fat diet chow high fat diet
TGF-b1 0.1 ± 0.0 0.9 ± 0.1b 1.1 ± 0.1b 1.1 ± 0.1b
PDGF-B 0.2 ± 0.1 1.8 ± 0.1a 1.7 ± 0.2a 2.4 ± 0.1b,d,e
PDGF 0.1 ± 0.1 2.2 ± 0.2b 1.4 ± 0.2b 2.1 ± 0.2b,c
receptor b
Abbreviations are: TGF-b1, transforming growth factor-b1; PDGF-B,
platelet-derived growth factor-B.
Semiquantitative scoring of glomerular mRNA expression for TGF-b ,
PDGF-B and PDGF receptor b . Data expressed as mean ± SEM. Statistical
significances compared to wild-type controls (aP < 0.01, bP < 0.001) or compared
to chow fed B6.ROP Os/+ animals (cP < 0.05, dP < 0.01). Differences between
C57BL/6 mice and B6.ROP Os/+ mice on high fat diet are expressed as eP <
0.01.
only few positive cells in glomeruli, interstitial cells or
cells of the vessel wall in the other experimental groups.
Consequently, no statistical analysis was not performed
for this parameter.
Hyperlipidemic mice do not develop obesity,
hyperglycemia, and insulin resistance
To assess whether the deterioration in renal function
and the aggravation of renal pathology was due to hy-
perlipidemia and not to changes mediated by obesity, hy-
perglycemia, or insulin resistance, body weight as well as
glucose and insulin levels were assessed in mice from all
experimental groups. Feeding a HFHC diet to C57BL/6
wild-type mice did not induce an increase in body weight
and did not influence glucose metabolism as indicated by
serum glucose and insulin levels (Table 1) as previously
described [25]. Similarly, feeding this diet to B6.ROP
Os/+ mice did not induce obesity (22.3 ± 1.2 g body
weight in chow fed B6.ROP Os/+ mice vs. 19.2 ± 0.5
g in B6.ROP Os/+ mice on the HFHC diet) and there
was no increase in glucose or insulin levels induced by
feeding the HFHC diet (Table 1).
DISCUSSION
The capacity of hyperlipidemia to initiate or signifi-
cantly contribute to chronic renal injury remains unset-
tled. In humans the role of hyperlipidemia in initiating
kidney disease seems to be limited to some rare forms
of metabolic abnormalities such as lecithin:cholesterol
acyltransferase (LCAT) deficiency [26] and disorders of
apolipoprotein E [27]. The extent to which hyperlipi-
demia might contribute to such chronic renal injury as
diabetes or nephrosclerosis is not yet clear. The situa-
tion is different in experimental settings where hyperlipi-
demia has been demonstrated to induce renal injury in a
variety of animal models such as dietary induced hyper-
lipidemia in rat [28–30], guinea pig [31], and rabbit [32],
as well as in genetic hyperlipidemia in the obese Zucker
rat [33] and the apolipoprotein E −/− mouse [34]. In
this study we examined the effect of hyperlipidemia in
mice with reduced nephron mass, a situation common in
humans as a result of aging, remote glomerulonephritis,
vascular disease, or nephrectomy. We demonstrate that
feeding a HFHC diet to C57BL/6 mice led to a decline
in renal excretory function and to the development of
proteinuria. These changes correlated with an increase in
mesangial matrix and cellularity and by tubulointerstitial
alterations including macrophage influx and an increased
turnover of tubular epithelial cells. In addition, we could
establish that hyperlipidemia aggravates renal injury in
B6.ROP Os/+ mice. Hyperlipidemic B6.ROP Os/+ an-
imals had an additional increase in plasma BUN levels
and showed augmentation of ROP Os/+ associated re-
nal pathology with the presence of mesangiolysis and a
further increase in glomerular matrix and cellularity com-
pared to normolipidemic B6.ROP Os/+ mice. Tubuloin-
terstitial changes consisted of fatty tubular degeneration
with an increase in the proliferation index of tubular ep-
ithelial cells and infiltration of macrophages/foam cells.
The mechanism by which hyperlipidemia exerts its
deleterious effect on the kidney is still largely unknown.
One mechanism by which hyperlipidemia may medi-
ate renal injury could be by directly acting on resi-
dent cells in the kidney. The glomerulus and the renal
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tubulointerstitium may be a preferred location for lipid
deposition and interaction with resident cells because
of the lack of a basement membrane separating the
mesangium and the capillary stream and the presence of
fenestrated epithelium lining glomerular and peritubu-
lar capillaries. Lipids can therefore easily access these
areas and influence local metabolism. Mesangial cells
have been shown to bind and take up native and ox-
idized low-density lipoprotein (LDL) cholesterol [35].
Binding of LDL and other lipoproteins to mesangial
cells has been shown to influence cellular proliferation
and stimulate secretion of inflammatory mediators like
prostanoids, interleukin-6 (IL-6), PDGF, and TGF-b [35–
38]. In addition, lipoproteins influence matrix generation
by stimulating mesangial fibronectin and collagen IV ex-
pression [39, 40]. Consistent with this scenario, we were
able to demonstrate that hyperlipidemic mice in our study
had increased levels of glomerular expression of TGF-b ,
PDGF-B and its receptor PDGF receptor b . The relative
expression of glomerular mRNA of these cytokines was
significantly correlated with the amount of glomerular
matrix and cellularity, respectively, making these growth
factors likely contributors to the injury process. How-
ever, our results demonstrate only a correlation and not
a definitive proof of causality.
Lipoproteins, the transport entities for lipids in the
blood, may play a role in renal injury as well. Apolipopro-
tein B has been linked to the development of atheroscle-
rosis and cardiovascular disease [41–43] and there have
also been some studies that demonstrate an association
of apolipoprotein B plasma levels and the progression
of renal insufficiency [12, 44–46]. Normolipidemic con-
trol and B6.ROP Os/+ mice in our study did not show
significant staining for apolipoprotein B in either
glomeruli or the tubulointerstitium. In contrast, hy-
perlipidemic C57BL/6 animals demonstrated diffuse
glomerular staining for apolipoprotein B and additional
staining of interstitial cells that morphologically appeared
to be infiltrating macrophages. In addition to this finding,
the hyperlipidemic B6.ROP Os/+ mice had frequent, fo-
cal staining for apolipoprotein B in the area of the vascu-
lar pole that could not be seen in hyperlipidemic control
animals. One explanation for this distinct staining pattern
could be that these mice have impaired clearing of lipids
through a mesangial pathway as an indicator of glomeru-
lar injury. However, our study does not address the issue
whether trapping of apolipoprotein B in the glomeruli it-
self is able to induce renal damage or if this localization
is incidental to the principal mechanism of tissue injury.
A mechanism that may be important in the me-
diation of lipid-induced renal injury involves infil-
trating macrophages. Lipids have been shown to
induce glomerular expression of chemoattractants such
as MCP-1, monocyte-colony-stimulating factor (M-CSF),
migration inhibitory factor (MIF), intercellular adhe-
sion molecule-1 (ICAM-1), and vascular cell adhesion
molecule-1 (VCAM-1) [47–49] and various animal mod-
els of hyperlipidemia-induced renal disease have demon-
strated increased influx of macrophages into glomeruli
[28, 30, 34, 50] and into the tubulointerstitium [23, 29,
51, 52] of affected animals. The functional importance of
macrophages in mediating renal injury in hyperlipidemic
states is highlighted by work done by Pesek-Diamond
et al [51] showing that depletion of macrophages resulted
in an amelioration of renal function impairment and
reduction of glomerulosclerosis and matrix expansion
in hyperlipidemic rats with acute puromycin aminonu-
cleoside nephrosis. Our studies tested this mechanism
by directly assessing monocyte/macrophage infiltration
and production of a major chemoattractant for these
cells, MCP-1. Hyperlipidemic C57BL/6 mice in our study
did not show significant expression of MCP-1 in ei-
ther the glomeruli or the interstitium, corresponding
to the low increase in glomerular macrophage content.
However, hyperlipidemia did induce tubulointerstitial in-
flux of macrophages/foam cells, presumably mediated by
chemoattractants other than MCP-1. Studies have also in-
dicated that macrophages from hyperlipidemic rats may
be a major source for increased TGF-b expression [23,
24], an important cytokine for mediating extracellular
matrix deposition [53]. Our study also demonstrated a
significant correlation between glomerular macrophage
content and TGF-b expression.
CONCLUSION
We have been able to show that hyperlipidemia leads
to significant renal injury associated with a decline in re-
nal function in healthy C57BL/6 control mice and that it
is able to aggravate renal injury of reduced renal mass in-
duced by the ROP Os/+mutation. TGF-b and the PDGF-
B system have been identified as two possible mediators
of this process.
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